Lumos Diagnostics has appointed healthcare investment expert Aizaz Syed as a non-executive director, representing its largest shareholder Tenmile Ventures. Syed replaces Lawrence Mehren, who steps down but remains an advisor to support US commercialisation. This move strengthens Lumos' board with strategic healthcare investment expertise as the company focuses on expanding its US market presence. The appointment will be voted on at the November 2026 annual general meeting.
Lumos Diagnostics' recent board appointment comes amid a balanced health sector market on Pluang, where 64 of 128 US health stocks rose and 64 fell as of Oct 13, 2026, 06:21 WIB. Among notable movers, Definium Therapeutics Inc. (DFTX) saw a price of USD 34.97 with a 1-day change of -5.23% and a typical hold time of 2 days, with Pluang order activity showing 100% buy. Twist Bioscience Corp (TWST) traded at USD 151.50, down 5.18%, with a 27-day hold time and 84% buy activity, while GeneDx Holdings Corp (WGS) was priced at USD 63.86, down 5.15%, with a 20-day hold time.
Kirby McInerney LLP is investigating Fervo Energy for potential securities law violations following the company's Q2 2026 earnings report and a critical research report. Fervo's shares fell sharply after it disclosed possible transmission issues at i...
Airbnb reports a surge in fall travel, with 60% of Americans planning weekend getaways, especially families with infants. Gen Z is driving a trend called lore-tripping, seeking unique local stories, while sports fans engage in groundhopping to iconic...
In Q3 2026, TRON DAO reported a milestone of $2.21 trillion in stablecoin settlements, with the network surpassing $30 trillion in cumulative transaction volume. The active user base grew by nearly 10%, and stablecoin supply increased to $93.88 billi...
Bureau Veritas disclosed its share buyback transactions conducted between October 5 and October 9, 2026. This activity reflects the company's ongoing efforts to manage its capital structure and potentially enhance shareholder value. Investors should ...
Bureau Veritas disclosed its treasury shares transactions conducted between October 5 and October 9, 2026. This update is part of the company's regular reporting obligations to inform investors about changes in its treasury shares holdings. Such disc...
